State of New Jersey Common Pension Fund D Increases Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

State of New Jersey Common Pension Fund D increased its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 95.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,316 shares of the company’s stock after purchasing an additional 12,387 shares during the quarter. State of New Jersey Common Pension Fund D owned 0.08% of TransMedics Group worth $1,578,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Principal Financial Group Inc. raised its position in TransMedics Group by 260.1% in the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after purchasing an additional 146,115 shares during the last quarter. Public Sector Pension Investment Board purchased a new position in TransMedics Group during the third quarter worth $11,079,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in TransMedics Group by 665.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock valued at $11,716,000 after purchasing an additional 64,872 shares in the last quarter. Vaughan Nelson Investment Management L.P. increased its stake in shares of TransMedics Group by 24.3% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after acquiring an additional 64,360 shares during the last quarter. Finally, WCM Investment Management LLC purchased a new stake in TransMedics Group during the 3rd quarter worth $8,720,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 7.00% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on TMDX. Oppenheimer restated an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Piper Sandler dropped their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Finally, Canaccord Genuity Group reduced their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $73.00 on Wednesday. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The stock has a market capitalization of $2.45 billion, a P/E ratio of 77.66 and a beta of 2.12. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The business has a 50-day moving average price of $66.89 and a two-hundred day moving average price of $103.27.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.